The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
To foster more sustainable change in the delivery of skin care beyond teledermatology and periodic visits from volunteers, some dermatology residencies have established partnerships with tribes.